Future therapeutic targets in mood disorders: The glucocorticoid receptor

131Citations
Citations of this article
97Readers
Mendeley users who have this article in their library.

Abstract

Background. The hypercortisolaemia and dysfunction of the hypothalamic pituitary - adrenal (HPA) axis associated with mood disorders have been attributed to a breakdown in the glucocorticoid-receptor-mediated negative feedback mechanism regulating HPA activity. Reinstating normal feedback may be therapeutic in mood disorders. Aims. To review the evidence for the involvement of the glucocorticoid receptor in the pathogenesis and treatment of mood disorders. Method. Medline and hand searches were carried out, selecting literature relevant to psychiatrists and psychopharmacologists. Results. A dysfunction in glucocorticoid receptors is integral to the HPA abnormalities of mood disorders. Antidepressant and mood-stabilising drugs can up-regulate glucocorticoid receptors, restoring glucocorticoid function. Preliminary clinical studies targeting the glucocorticoid receptor are encouraging. Conclusions. Drugs designed specifically to up-regulate glucocorticoid receptors may be integral to future strategies in treating mood disorders. Declaration of interest. None.

Cite

CITATION STYLE

APA

McQuade, R., & Young, A. H. (2000). Future therapeutic targets in mood disorders: The glucocorticoid receptor. British Journal of Psychiatry. https://doi.org/10.1192/bjp.177.5.390

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free